AtaiBeckley Inc. is working with advisers to explore options for its flagship psychedelic drug candidate, according to people familiar with the matter.
The firm is looking at a potential sale or partnership for BPL-003, a nasal spray for treatment of severe depression that’s entering phase 3 clinical trials, the people said. AtaiBeckley is aiming to fetch $2 billion or more from a deal and has picked Jefferies Financial Group Inc. and JPMorgan Chase & Co. to lead talks with other pharmaceutical companies, said the people, who asked not to be identified as the information is private.
Under a co-commercialization agreement, ...
